Senesco Technologies, Inc. Opens New Clinical Trial Site at Seattle Cancer Care Alliance and is Treating the First West Coast Patient

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB:SNTID) reported the treatment of the first patient at the Company’s newly opened clinical-trial site at Seattle Cancer Care Alliance (SCCA). This patient is part of Senesco’s Phase 1b/2a clinical study of its therapeutic drug candidate, SNS01-T, targeting B-cell cancers.

Help employers find you! Check out all the jobs and post your resume.

Back to news